英格兰大型中心产碳青霉烯酶肠杆菌目细菌的耐药谱:我们是否正在失去头孢地尔
该研究回顾性分析2020年8月1日至2023年8月31日英格兰一家大型教学信托机构158株非重复产碳青霉烯酶肠杆菌目细菌(CPE)分离株。OXA-48最常见(48.1%),其次NDM(38%);NDM产酶株中69.7%对头孢地尔耐药,另有18.2%处于技术不确定区。作者结论认为其结果禁止在本机构经验性使用头孢地尔治疗CPE感染。
要点
- OXA-48为最常见碳青霉烯酶(48.1%),其次为NDM(38%)。
- NDM产酶株中69.7%对头孢地尔耐药,另18.2%处于技术不确定区。
- 作者认为本机构结果禁止经验性使用头孢地尔治疗CPE感染。
核心结论
- 在无头孢地尔暴露史的CPE分离株中发现高比例头孢地尔耐药;作者认为该结果禁止在本机构经验性使用头孢地尔治疗CPE感染。
研究设计与样本
- 回顾性研究2020年8月1日至2023年8月31日英格兰一家大型教学信托机构的全部非重复CPE分离株。
- 头孢地尔药敏采用纸片扩散法,头孢噻肟/阿维巴坦采用纸片扩散法和梯度扩散法,头孢噻肟/阿维巴坦与氨曲南协同采用双纸片扩散法,判读采用EUCAST 14.0版折点。
主要发现
- 共从136例患者分离158株CPE;多数患者为定植,仅16.9%为活动性感染。
- 30天全因死亡率为10.3%,感染患者为13%,菌血症患者为18.2%。
- OXA-48为最常见碳青霉烯酶(48.1%),其次为NDM(38%);所有分离株均呈多重耐药,对美罗培南耐药率为41.1%。
- NDM产酶株中69.7%对头孢地尔耐药,另有18.2%处于技术不确定区;头孢噻肟/阿维巴坦与氨曲南协同见于87.5%分离株,黏菌素和磷霉素敏感率分别为98.1%和97.2%。
- 所有OXA-48产酶株对头孢噻肟/阿维巴坦敏感,其中15.3%对头孢地尔耐药;无患者既往暴露于头孢地尔,3例既往暴露于头孢噻肟/阿维巴坦;CPE分离最常见风险因素为旅行和在国外接受医疗照护,尤其是亚洲。
临床怎么用
- 作者认为,基于本机构结果,不应经验性使用头孢地尔治疗CPE感染。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Carbapenemase-producing Enterobacterales (CPE) pose difficult therapeutic challenges. We aimed to characterize antimicrobial resistance profiles of CPE in our centre. METHODS: All non-duplicate CPE isolates between 1 August 2020 and 31 August 2023 in a large teaching trust in England were retrospectively studied. Cefiderocol antimicrobial susceptibility testing (AST) was performed using disc diffusion, ceftazidime/avibactam using disc diffusion and gradient diffusion, and ceftazidime/avibactam aztreonam synergy using the double disc diffusion method. EUCAST version 14.0 breakpoints were used. RESULTS: A total of 158 CPE from 136 patients were isolated. Most patients were colonized with CPE, but only 16.9% had active infections. Thirty-day all-cause mortality was 10.3%, increasing to 13% for patients with infections and to 18.2% for bacteraemias. OXA-48 was the most prevalent carbapenemase (48.1%), followed by NDM (38%). All isolates exhibited MDR profiles, with high levels of resistance to meropenem (41.1%). Resistance to cefiderocol was found in 69.7% of NDM-producing isolates, with a further 18.2% in the area of technical uncertainty. Ceftazidime/avibactam and aztreonam synergy was seen in 87.5% of isolates, whereas colistin and fosfomycin susceptibility remained high (98.1% and 97.2%, respectively). All OXA-48-producing isolates were susceptible to ceftazidime/avibactam, and 15.3% were resistant to cefiderocol. No patients had been exposed to cefiderocol beforehand, whereas three had been exposed to ceftazidime/avibactam. The most common risk factor for CPE isolation was travel and receiving healthcare abroad, especially in Asia. CONCLUSIONS: We found high rates of resistance to cefiderocol in CPE isolates without prior cefiderocol exposure. Our results prohibit empirical use of cefiderocol for the treatment of CPE infections in our setting.
引用
- Baltas I, Patel T, Soares AL, et al. Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol? J Antimicrob Chemother. 2025. PMID: 39504496. doi:10.1093/jac/dkae367
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。